Trial to Assess Long-Term Persistence of Antibodies after GSK Meningococcal ABCWY Vaccination and Response to a Booster in Adolescents

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002230-69

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Effectiveness: To evaluate the effectiveness of 3 doses of MenABCWY (administered according to a 0, 2, 6-month schedule) against a randomly selected panel of US endemic N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity at 1:4 dilution using enc-hSBA, compared with 2 doses of MenABCWY (administered according to a 0, 2-month schedule), at 24 months after the last meningococcal vaccination in study V102_15.


Critère d'inclusion

  • Meningococcal diseases

Liens